MedKoo Cat#: 406296 | Name: TNKS656
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

NVP-TNKS656, also known as TNKS656, is a potent and orally active Tankyrase Inhibitor. With an enthalpy-driven thermodynamic signature of binding, highly favorable physicochemical properties, and high lipophilic efficiency, NVP-TNKS656 is well suited for further in vivo validation studies. Bioactivity of TNKS656: TNKS2 IC50 = 6nM, LiPE = 7.0, HEK298 STF IC50 = 3.5nM, Cmax/ Cellular IC50 = 23,000

Chemical Structure

TNKS656
TNKS656
CAS#1419949-20-4

Theoretical Analysis

MedKoo Cat#: 406296

Name: TNKS656

CAS#: 1419949-20-4

Chemical Formula: C27H34N4O5

Exact Mass: 494.2529

Molecular Weight: 494.58

Elemental Analysis: C, 65.57; H, 6.93; N, 11.33; O, 16.17

Price and Availability

Size Price Availability Quantity
25mg USD 450.00 2 Weeks
50mg USD 750.00 2 Weeks
100mg USD 1,250.00 2 Weeks
200mg USD 2,250.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
NVP-TNKS656; NVP-TNKS-656;NVP-TNKS 656;TNKS656; TNKS-656; TNKS 656;
IUPAC/Chemical Name
N-(cyclopropylmethyl)-2-(4-(4-methoxybenzoyl)piperidin-1-yl)-N-((4-oxo-4,5,7,8-tetrahydro-3H-pyrano[4,3-d]pyrimidin-2-yl)methyl)acetamide
InChi Key
DYGBNAYFDZEYBA-UHFFFAOYSA-N
InChi Code
InChI=1S/C27H34N4O5/c1-35-21-6-4-19(5-7-21)26(33)20-8-11-30(12-9-20)16-25(32)31(14-18-2-3-18)15-24-28-23-10-13-36-17-22(23)27(34)29-24/h4-7,18,20H,2-3,8-17H2,1H3,(H,28,29,34)
SMILES Code
O=C1NC(CN(CC2CC2)C(CN3CCC(C(C4=CC=C(OC)C=C4)=O)CC3)=O)=NC5=C1COCC5
Appearance
solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
  Bioacitivity of TNKS656  Data  was copied from J Med Chem. 2013 Aug 22;56(16):6495-511.  Data  was copied from      

Preparing Stock Solutions

The following data is based on the product molecular weight 494.58 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Yun H, You JE, Hong JK, Kim DY, Lee JU, Kang DH, Ryu YS, Koh DI, Jin DH. TCOF1 promotes the colorectal cancer progression by stabilizing β-catenin. Med Oncol. 2023 Nov 7;40(12):348. doi: 10.1007/s12032-023-02218-z. PMID: 37935810. 2: Asano Y, Matsumoto Y, He F, Katsuyama T, Katsuyama E, Tsuji S, Kamioka H, La Rose J, Rottapel R, Wada J. Pharmacologic inhibition of PARP5, but not that of PARP1 or 2, promotes cytokine production and osteoclastogenesis through different pathways. Clin Exp Rheumatol. 2023 Sep;41(9):1735-1745. doi: 10.55563/clinexprheumatol/qf55h8. Epub 2023 Jan 23. PMID: 36700637. 3: Huang J, Qu Q, Guo Y, Xiang Y, Feng D. Tankyrases/β-catenin Signaling Pathway as an Anti-proliferation and Anti-metastatic Target in Hepatocarcinoma Cell Lines. J Cancer. 2020 Jan 1;11(2):432-440. doi: 10.7150/jca.30976. PMID: 31897238; PMCID: PMC6930431. 4: Katoh M. Multi‑layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β‑catenin signaling activation (Review). Int J Mol Med. 2018 Aug;42(2):713-725. doi: 10.3892/ijmm.2018.3689. Epub 2018 May 17. PMID: 29786110; PMCID: PMC6034925. 5: Katoh M. Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review). Int J Oncol. 2017 Nov;51(5):1357-1369. doi: 10.3892/ijo.2017.4129. Epub 2017 Sep 19. PMID: 29048660; PMCID: PMC5642388. 6: Arqués O, Chicote I, Puig I, Tenbaum SP, Argilés G, Dienstmann R, Fernández N, Caratù G, Matito J, Silberschmidt D, Rodon J, Landolfi S, Prat A, Espín E, Charco R, Nuciforo P, Vivancos A, Shao W, Tabernero J, Palmer HG. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. Clin Cancer Res. 2016 Feb 1;22(3):644-56. doi: 10.1158/1078-0432.CCR-14-3081. Epub 2015 Jul 29. PMID: 26224873. 7: Shultz MD, Cheung AK, Kirby CA, Firestone B, Fan J, Chen CH, Chen Z, Chin DN, Dipietro L, Fazal A, Feng Y, Fortin PD, Gould T, Lagu B, Lei H, Lenoir F, Majumdar D, Ochala E, Palermo MG, Pham L, Pu M, Smith T, Stams T, Tomlinson RC, Touré BB, Visser M, Wang RM, Waters NJ, Shao W. Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitor. J Med Chem. 2013 Aug 22;56(16):6495-511. doi: 10.1021/jm400807n. Epub 2013 Aug 13. PMID: 23844574.